.png "IgA Nephropathy Market")
IgA Nephropathy Market Overview
An autoimmune condition known as IgA Nephropathy (IgAN) assaults the kidneys and impairs blood filtration in the tiny blood capillaries of the kidneys. It happens when an aberrant protein harms the glomerulus, which serves as the kidneys' filtering system.
IgA Nephropathy Epidemiology Insights (2022)
The Total IgA Nephropathy prevalent cases in the 7MM + China were ~1.8 million in 2022
IgA Nephropathy Market Insight (2022)
The IgA Nephropathy Market size in the 7MM was valued ~USD 500 million in 2022
IgA Nephropathy Market Strengths
- New drugs with diverse mechanisms of action
- Advances in disease nomenclature for classification, clinical trials, drug delivery systems
IgA Nephropathy Market Opportunities
- Opportunity for companies to implement knowledge from recent advances
- Discovery of biomarker and proteomics
IgA Nephropathy Emerging Drugs and Key Companies
- Narsoplimab: Omeros Corporation
- Iptacopan (LNP023): Novartis Pharmaceuticals
- Atrasentan: Chinook Therapeutics
- Sibeprenlimab (VIS-649): Visterra (a subsidiary of Otsuka Pharmaceutical)
- Cemdisiran: Alnylam Pharmaceuticals
- Atacicept (VT-001): Vera Therapeutics
- Telitacicept (RC18): RemeGen
- BION-1301: Chinook Therapeutics, and others